# Se-Hoon Lee

Source: https://onco.cc/people/lee-se-hoon/  
OnCo record `lee-se-hoon` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.

## Summary

Se-Hoon Lee is Professor of Internal Medicine at Seoul National University Hospital, working in thoracic oncology and immunotherapy. He has helped test checkpoint inhibitors and next-generation antibody-drug conjugates in Korean patients, including the datopotamab deruxtecan and tarlatamab programmes in non-small-cell and small-cell lung cancer. His publications include a phase 2 trial of vandetanib in pretreated lung cancer harbouring RET rearrangements and a study of the clonal history and genetic predictors of transformation from lung adenocarcinoma into small-cell carcinoma. His interests are lung cancer, immunotherapy and small-cell lung cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Internal Medicine; thoracic oncology and immunotherapy
- Specialisms: Lung cancer; Immunotherapy; Small-cell lung cancer

## Sources

- Seoul National University Hospital: https://www.snuh.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SH%5BAuthor%5D%20Seoul%20National%20University%20lung%20immunotherapy

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- institutions: [Seoul National University Hospital](https://onco.cc/institutions/snuh/)
- key papers: [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/lee-se-hoon.json